The incidence of KRAS mutation in duodenal adenoma, early-stage duodenal adenocarcinoma, and advanced-stage duodenal adenocarcinoma was 18.1%, 17.7%, and 31.2%, respectively, with no significant differences (P = 0.20). This evidence concerns the gene KRAS and duodenal adenocarcinoma.